Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance

Cancer Research

Volumn 73, Issue 20, 2013, Pages 6359-6374

  Zhang, Yaqing ^a   Yan, Wei ^a,b   Collins, Meredith A ^a   Bednar, Filip ^a   Rakshit, Sabita ^a   Zetter, Bruce R ^e   Stanger, Ben Z ^f,g   Chung, Ivy ^g,h   Rhim, Andrew D ^c   Di Magliano, Marina Pasca ^a,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d Karp Family Research Laboratories   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF MALAYA   (Malaysia)

^h FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; K RAS PROTEIN; MATRILYSIN; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN KINASE B; STAT3 PROTEIN; TRANSCRIPTION FACTOR NRF2;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAK GENE; BAX GENE; BCL X GENE; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DETOXIFICATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE INACTIVATION; GM CSF GENE; HUMAN; HUMAN CELL; IL1BETA GENE; IL6 GENE; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; INTRACELLULAR SIGNALING; MMP7 GENE; MMP9 GENE; MOLECULAR PATHOLOGY; MOUSE; MT1 MMP GENE; NONHUMAN; ONCOGENE K RAS; OXIDATIVE STRESS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTO ONCOGENE; SLFN4 GENE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; UPREGULATION;

ANIMALS; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; OXIDATIVE STRESS; PANCREATIC NEOPLASMS; RANDOM ALLOCATION;

EID: 84886002334     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1558-T     Document Type: Article

References (53)

1. Katz MH, Wang H, Fleming J.B., Sun CC, Hwang RF, Wolff RA, et al Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009; 16:836-47.
2. National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) Program. Available from: http://seer.cancer.gov.
3. American Cancer Society. Cancer facts and figures. Available from: http://www.cancer.org/Research/CancerFactsFigures.
4. Biankin AV, Kench JG, Dijkman F.P., Biankin SA, Henshall SM Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma. Pathology 2003; 35:14-24.
5. Smit VT, Boot AJ, Smits A.M., Fleuren GJ, Cornelisse CJ, Bos JL KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988; 16:7773-82.
6. Almoguera C, Shibata D, Forrester K., Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53:549-54.
7. Kanda M, Matthaei H, Wu J., Hong SM, Yu J, Borges M, et al Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012; 142:730-3.
8. Yan L, McFaul C, Howes N., Leslie J, Lancaster G, Wong T., et al Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 2005; 128:2124-30.
9. Parsons BL, Meng F. K-RAS mutation in the screening, prognosis and treatment of cancer. Biomark Med 2009; 3:757-69.
10. Lowenfels AB, Maisonneuve P, Cavallini G., Ammann RW, Lankisch PG, Andersen JR, et al Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328:1433-7.
11. Lankisch PG, Breuer N, Bruns A., Weber-Dany B, Lowenfels AB, Maisonneuve P. Natural history of acute pancreatitis: a long-term population-based study. Am J Gastroenterol 2009; 104:2797-805.
12. Morris J IV, Cano D.A., Sekine S., Wang SC, Hebrok M. Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J Clin Invest 2010; 120:508-20.
13. Guerra C, Collado M, Navas C., Schuhmacher AJ, Hernandez-Porras I, Canamero M, et al Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011; 19:728-39.
14. Talar-Wojnarowska R., Gasiorowska A, Smolarz B., Romanowicz Makowska H, Kulig A, Malecka-Panas E. Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 2009; 54:683-9.
15. Grivennikov S, Karin E, Terzic J., Mucida D, Yu GY, Vallabhapurapu S, et al IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15:103-13.
16. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14:109-19.
17. Howlett M, Giraud AS, Lescesen H, Jackson C.B., Kalantzis A., Van Driel IR, et al The interleukin-6 family cytokine interleukin-11 regulates homeostatic epithelial cell turnover and promotes gastric tumor development. Gastroenterology 2009; 136:967-77.
18. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M., Kloppel G, et al Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011; 19:456-69.
19. Fukuda A, Wang SC, Morris J IV, Folias AE, Liou A, Kim GE, et al Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011; 19:441-55.
20. Corcoran RB, Contino G, Deshpande V., Tzatsos A, Conrad C, Benes C.H., et al STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 2011; 71:5020-9.
21. Collins MA, Bednar F, Zhang Y., Brisset JC, Galban S, Galban CJ, et al Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012; 122: 639-53.
22. Rhim AD, Mirek ET, Aiello N.M., Maitra A., Bailey JM, McAllister F, et al EMT and dissemination precede pancreatic tumor formation. Cell 2012; 148:349-61.
23. Li C, Heidt DG, Dalerba P, Burant C.F., Zhang L., Adsay V, et al Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
24. Collins MA, Brisset JC, Zhang Y, Bednar F., Pierre J, Heist KA, et al Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS ONE 2012; 7:e49707.
25. Duan RD, Zheng CF, Guan K.L., Williams JA Activation of MAP kinase kinase (MEK) and Ras by cholecystokinin in rat pancreatic acini. Am J Physiol 1995; 268:G1060-5.
26. Duan RD, Williams JA Cholecystokinin rapidly activates mitogenactivated protein kinase in rat pancreatic acini. Am J Physiol 1994; 267:G401-8.
27. Lupia E, Goffi A, De Giuli P, Azzolino O, Bosco O., Patrucco E, et al Ablation of phosphoinositide 3-kinase-gamma reduces the severity of acute pancreatitis. Am J Pathol 2004; 165:2003-11.
28. Clark CE, Hingorani SR, Mick R, Combs C., Tuveson DA, Vonderheide RH Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007; 67:9518-27.
29. Chang DZ, Ma Y, Ji B., Wang H, Deng D, Liu Y., et al Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin Cancer Res 2011; 17:7015-23.
30. van Zuylen W.J., Garceau V, Idris A., Schroder K, Irvine KM, Lattin J.E., et al Macrophage activation and differentiation signals regulate schlafen-4 gene expression: evidence for Schlafen-4 as a modulator of myelopoiesis. PLoS ONE 2011; 6:e15723.
31. Bayne LJ, Beatty GL, Jhala N, Clark C.E., Rhim AD, Stanger BZ, et al Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012; 21:822-35.
32. Pylayeva-Gupta Y., Lee KE, Hajdu C.H., Miller G., Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012; 21:836-47.
33. Direnzo D, Hess DA, Damsz B, Hallett J.E., Marshall B., Goswami C, et al Induced Mist1 expression promotes remodeling of mouse pancreatic acinar cells. Gastroenterology 2012; 143:469-80.
34. Shi G, Zhu L, Sun Y., Bettencourt R, Damsz B, Hruban R.H., et al Loss of the acinar-restricted transcription factor Mist1 accelerates Krasinduced pancreatic intraepithelial neoplasia. Gastroenterology 2009; 136:1368-78.
35. Shi G, Direnzo D, Qu C., Barney D, Miley D, Konieczny SF Maintenance of acinar cell organization is critical to preventing Kras-induced acinarductal metaplasia. Oncogene 2013; 32:1950-8.
36. DeNicola GM, Karreth FA, Humpton T.J., Gopinathan A., Wei C, Frese K, et al Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011; 475:106-9.
37. Recktenwald CV, Kellner R, Lichtenfels R., Seliger B. Altered detoxification status and increased resistance to oxidative stress by K-ras transformation. Cancer Res 2008; 68:10086-93.
38. Papaiahgari S, Kleeberger SR, Cho H.Y., Kalvakolanu DV, Reddy SP NADPH oxidase and ERK signaling regulates hyperoxia-induced Nrf2ARE transcriptional response in pulmonary epithelial cells. J Biol Chem 2004; 279:42302-12.
39. Hingorani SR, Wang L, Multani A.S., Combs C., Deramaudt TB, Hruban RH, et al Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7:469-83.
40. Singh M, Lima A, Molina R., Hamilton P, Clermont AC, Devasthali V, et al Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 2010; 28:585-93.
41. Clark CE, Beatty GL, Vonderheide RH Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett 2009; 279:1-7.
42. Morris J IV, Wang S.C., Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010; 10:683-95.
43. Kopp JL, von Figura G, Mayes E, Liu F.F., Dubois CL, Morris J IV, et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 22:737-50.
44. Ancrile B, Lim KH, Counter CM Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007; 21:1714-9.
45. Ardito CM, Gruner BM, Takeuchi K.K., Lubeseder-Martellato C, Teichmann N, Mazur P.K., et al EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012; 22: 304-17.
46. Navas C, Hernandez-Porras I, Schuhmacher A.J., Sibilia M., Guerra C, Barbacid M. EGF receptor signaling is essential for k-ras oncogenedriven pancreatic ductal adenocarcinoma. Cancer Cell 2012; 22: 318-30.
47. Daniluk J, Liu Y, Deng D., Chu J, Huang H, Gaiser S., et al An NFkappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 2012; 122: 1519-28.
48. Collisson EA, Trejo CL, Silva J.M., Gu S., Korkola JE, Heiser LM, et al A central role for RAF → MEK → ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2012; 2:685-93.
49. Venugopal R, Jaiswal AK Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 1998; 17:3145-56.
50. Shibutani S, Takeshita M, Grollman AP Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 1991; 349:431-4.
51. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009; 34:176-88.
52. Tu S, Bhagat G, Cui G., Takaishi S, Kurt-Jones EA, Rickman B, et al Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008; 14:408-19.
53. Guo Y, Xu F, Lu T., Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38:904-10.